Fonterra Shareholders' Fund logo

Fonterra achieves $1 billion debt reduction

M&A24 September 2019FSFConsumer Staples

25 SEPTEMBER 2019

FONTERRA ACHIEVES $1 BILLION DEBT REDUCTION


Fonterra today agreed the sale of its 50% share of DFE Pharma for $633

1

million (NZD). The cash from

this sale, along with proceeds from our other asset sales across the year – which includes the significant

contribution from Tip Top – will give us over $1 billion available for debt reduction.


Fonterra CEO, Miles Hurrell, says “we set ourselves a tough initial target for debt reduction and we are

pleased with the progress we are making. It’s an important milestone in our Co-op’s plan to lift our

business performance.


“A year ago, we started a full portfolio review to re-evaluate every investment, major asset and

partnership, to make sure they were still right for the Co-op.


“In March, we advised that we were reviewing our share of DFE Pharma, a 50% joint venture with Royal

Friesland Campina. DFE Pharma was identified for sale due to the substantial capital required for its

future growth.


“We are now at the end of that process and have sold our share of DFE Pharma to CVC Strategic

Opportunities II, a fund managed by CVC Capital Partners, a leading private equity and investment

advisory firm, managing approximately US$83 billion of assets in 73 companies worldwide,” Mr Hurrell

says.


The $633 million sale to CVC Strategic Opportunities II is made up of a cash payment of $537 million,

payable on completion of the sale, plus an interest-accruing vendor loan of $96 million, for a term of up to

15 years. Built into the deal is a potential additional payment of up to $44 million based on DFE’s

performance over two years.


The sale is subject to receipt of regulatory approvals from competition authorities.


Mr Hurrell said that Fonterra was pleased to have secured a good sale price and will stay committed to

the ongoing success of the DFE Pharma business through a long-term supply agreement and the interest-

accruing vendor loan.


“A big part of the success of DFE Pharma has been the high-quality lactose produced by the team at

Fonterra’s Kapuni site in Taranaki and it is a good outcome to be able to continue to supply this.


“This milestone, along with the significant inroads made in our capital and operational expenditure during

FY19, makes for a good initial chapter in our business turn-around. It puts us on the right footing to

deliver our new strategy and a sustainable lift in our performance.” says Mr Hurrell.



-ENDS-




1

Numbers are based on Euro to NZD conversion rate of 1.17475

Fonterra Co-operative Group
Confidential to Fonterra Co-operative Group Page 2


For further information contact:


Fonterra Communications

24-hour media line

Phone: +64 21 507 072

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.